Anebulo Pharmaceuticals (NASDAQ:ANEB) Posts Earnings Results, Beats Estimates By $0.08 EPS

Anebulo Pharmaceuticals (NASDAQ:ANEB) issued its earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.08, Yahoo Finance reports.

Anebulo Pharmaceuticals Stock Performance

Shares of NASDAQ:ANEB opened at $2.05 on Friday. Anebulo Pharmaceuticals has a 52-week low of $1.62 and a 52-week high of $3.61. The business’s 50 day simple moving average is $2.05 and its two-hundred day simple moving average is $2.35. The firm has a market cap of $53.16 million, a P/E ratio of -5.54 and a beta of -1.01.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.